Brokerages forecast that BioScrip Inc (NASDAQ:BIOS) will announce earnings per share of ($0.10) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for BioScrip’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.12). BioScrip reported earnings per share of ($0.14) in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The company is scheduled to report its next earnings report on Tuesday, August 6th.

On average, analysts expect that BioScrip will report full-year earnings of ($0.26) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.23). For the next fiscal year, analysts forecast that the company will report earnings of ($0.16) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover BioScrip.

BioScrip (NASDAQ:BIOS) last posted its earnings results on Thursday, May 2nd. The company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The company had revenue of $178.96 million for the quarter, compared to the consensus estimate of $179.23 million. During the same quarter last year, the business earned ($0.12) earnings per share. BioScrip’s quarterly revenue was up 6.2% on a year-over-year basis.

Several research firms have weighed in on BIOS. Barrington Research restated a “buy” rating and set a $4.00 target price on shares of BioScrip in a report on Friday, May 3rd. TheStreet lowered Red Lion Hotels from a “c” rating to a “d+” rating in a report on Wednesday, April 3rd. Zacks Investment Research upgraded Hanmi Financial from a “sell” rating to a “hold” rating in a report on Thursday, June 20th. Finally, BidaskClub upgraded WhiteHorse Finance from a “sell” rating to a “hold” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $4.60.

Several institutional investors have recently bought and sold shares of BIOS. BlackRock Inc. increased its stake in shares of BioScrip by 28.8% in the fourth quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock worth $35,013,000 after purchasing an additional 2,191,490 shares during the period. Rothschild & Co. Asset Management US Inc. increased its stake in BioScrip by 68.1% during the first quarter. Rothschild & Co. Asset Management US Inc. now owns 3,812,471 shares of the company’s stock valued at $7,625,000 after acquiring an additional 1,545,050 shares during the period. Deutsche Bank AG increased its stake in BioScrip by 104.5% during the fourth quarter. Deutsche Bank AG now owns 724,410 shares of the company’s stock valued at $2,584,000 after acquiring an additional 370,177 shares during the period. Two Sigma Investments LP increased its stake in BioScrip by 81.2% during the fourth quarter. Two Sigma Investments LP now owns 767,882 shares of the company’s stock valued at $2,741,000 after acquiring an additional 344,013 shares during the period. Finally, Stephens Inc. AR bought a new position in BioScrip during the first quarter valued at about $405,000. Institutional investors and hedge funds own 78.60% of the company’s stock.

NASDAQ BIOS traded up $0.07 during trading on Friday, hitting $2.85. 1,008,791 shares of the company traded hands, compared to its average volume of 996,602. BioScrip has a 12 month low of $1.56 and a 12 month high of $4.14. The business’s fifty day simple moving average is $2.39. The company has a market cap of $357.95 million, a P/E ratio of -5.82 and a beta of 0.68.

BioScrip Company Profile

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Read More: What is a Roth IRA?

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with's FREE daily email newsletter.